



Variation in Biofilm-Forming Potential of *Staphylococcus aureus* from Clinical and Non-Clinical Sources

K. Otokunefor^{1*}, J. J. Jesutobi¹ and O. E. Agbagwa¹

¹*Department of Microbiology, Faculty of Science, University of Port Harcourt, Rivers State, Nigeria.*

Authors' contributions

This work was carried out in collaboration among all authors. Authors KO and OEA designed the study. Author JJJ carried out most of the lab work. Author KO wrote the first draft. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JAMB/2021/v21i130314

Editor(s):

(1) Prof. Hung-Jen Liu, National Chung Hsing University, Taiwan.

Reviewers:

(1) Nivedita Daimiwal, Cummins College of Engineering for Women, India.

(2) Jayvadan Patel, Sankalchand Patel University, India.

Complete Peer review History: <http://www.sdiarticle4.com/review-history/65069>

Original Research Article

Received 06 November 2020

Accepted 10 January 2021

Published 14 February 2021

ABSTRACT

Introduction: Biofilm forming ability has been described as a potential marker of pathogenicity, particularly in *Staphylococcus aureus*. These biofilms are notable as an important contributor to virulence abilities, further aiding the producing strain in long term survival and resistance to antimicrobial agents. Regional data exploring biofilm forming ability of *S. aureus* from various sources is limited. This study therefore set out to explore variations in biofilm-forming potential of *S. aureus* from clinical and non-clinical sources.

Place and Duration of Study: Medical Microbiology Laboratory, Department of Microbiology, University of Port Harcourt, Nigeria from August to October 2019.

Methodology: Eighty five *S. aureus* clinical and non-clinical isolates were studied. Biofilm-forming potential was assessed using the Congo Red agar (CRA) method which describes both the presence and degree biofilm-forming potential.

Results: Majority of isolates (65.9%) did not exhibit any biofilm-forming potential using the CRA method. Biofilm-forming potential however appeared source based with 100% of non-clinical *S. aureus* isolates lacking biofilm-forming potential, while 58% of clinical isolates showed biofilm-

*Corresponding author: E-mail: kome.otokunefor@uniport.edu.ng;

forming potential. A higher proportion (65.5%) of the clinical isolates exhibiting biofilm-forming potential where associated with strong biofilm-forming potential.

Conclusion: This study reports a high association of biofilm-forming potential with *S. aureus* isolated from clinical rather than non-clinical settings. If this characteristic can indeed be used as a general marker of pathogenicity would however require more extensive studies.

Keywords: Biofilm-forming; CRA; *Staphylococcus aureus*; Nigeria; pathogenicity.

1. INTRODUCTION

Though notable as one of the two main causative agents associated with human bacterial infections [1], *Staphylococcus aureus* is also a known commensal, found in association with various systems of the body without causing harm [2]. In addition to being a leading bacteria isolated in clinical microbiology practice, *S. aureus* has also been widely isolated from non-clinical sources such as food, water, environment and inanimate surfaces. *S. aureus* is notorious for its repertoire of associated virulence genes encoding staphylococcal enterotoxin, exfoliative toxins, hemolysins and toxic shock syndrome toxin [3].

Studies on the determining factors differentiating pathogenic and commensal strains of *S. aureus* are still widely ongoing. Several studies found a higher association of staphylococcal enterotoxin and enterotoxin-like genes with clinical strains of *S. aureus*. Aung and colleagues reported prevalence rates ranging from 5.6% to 92.9% [4]. Li and colleagues studying 11 different virulence genes, noted prevalence rates ranging from 15.4% to 100%. Though for 8 of the 11 genes assayed for, prevalence rates were above 35% [5]. A 2016 study, on 14 virulence genes in clinical isolates similarly noted prevalence rates ranging from 3.2% to 100%. Rates above 35% were found to occur only in 6 of the virulence genes [6]. This was opposed to a lower association of these genes with strains of *S. aureus* from food, animals and the environment [7]. Chao and colleagues noted a significantly higher ($P<0.01$) representation of classic staphylococcal enterotoxin genes in foodborne and human isolates than in animal isolates [8]. A 2019 study on enterotoxin carriage in isolates from food handlers, reported rates ranging from 2.7% to 40.2% [9].

Characterization of *S. aureus* from fish revealed prevalence rates ranging from 3 to 12% [10]. While a recent study reporting on isolates from ready to eat foods noted prevalence rates ranging from 18.8% to 56.3% [11]. Much lower prevalence rates (0% to 21.8%) were noted in a

study on *S. aureus* isolated from insects [12]. And other studies have noted a variation in gene expression levels rather than in the gene presence [13].

Biofilm forming ability is one of the different characteristics which have been examined in exploring differences between commensal and pathogenic strains of *S. aureus* [14]. Biofilms are microbial communities occurring within a self-produced extracellular polymeric substance (EPS) matrix composed of cells adhered to each other and a solid surface [15]. These biofilms are notable as an important contributor to virulence abilities, further aiding the producing strain in long term survival and resistance to antimicrobial agents [16-19]. Biofilm forming ability has even further been described as a potential marker of pathogenicity particularly in *S. aureus* [14,20]. Of all the studies corroborating these facts, few have been carried out in Africa with only a handful of studies exploring biofilm forming potential with relation to source of isolates in Nigeria. Regional data is key because despite general trends, sometimes regional variations occur. This study therefore set out to explore variations in biofilm forming potential of *S. aureus* from various sources in a bid to highlight possible links to pathogenicity.

2. MATERIALS AND METHODS

2.1 Bacterial Isolates

Test bacterial isolates used in this study comprised a total of 85 *S. aureus* isolates. These isolates were obtained from the bacterial collection of the Bacteriology group, Medical Microbiology Unit, University of Port Harcourt. Isolates were stored in agar stab cultures at -4°C, and comprised of 35 non-clinical isolates and 50 clinical isolates. The identities of the isolates were confirmed using standard phenotypic biochemical test methods [21,22].

2.2 Analysis of Biofilm Forming Potential

The biofilm forming potential of the clinical and non-clinical *S. aureus* was assessed using a

previously described Congo Red agar (CRA) method [23]. In brief, this simply involved the culture of purified test isolates on Congo red agar plates. Following a 24 hour incubation at 37°C, isolates exhibiting biofilm forming abilities show up as black colonies, while red colonies are indicative of isolates lacking biofilm forming potential. Further, based on intensity of black pigmentation, isolates exhibiting biofilm forming potential could then be classed as having strong, moderate or weak potential [24,25].

3. RESULTS AND DISCUSSION

3.1 Results

An analysis of the biofilm-forming potential of the test isolates revealed that majority of the isolates (53/85, 65.9%) did not exhibit any biofilm-forming potential using the CRA test method (Fig. 1).

A further assessment of biofilm-forming potential however showed that the higher proportion of test isolates lacking biofilm-forming potential was related to source, as biofilm-forming potential was not detected in any of the non-clinical

isolates (Fig. 2). For the clinical isolates, the majority of isolates (29/50, 58%) actually exhibited biofilm-forming potential.

Furthermore, a higher proportion (19/29, 65.5%) of the clinical isolates exhibiting biofilm-forming potential where associated with strong biofilm-forming potential (Fig. 3).

3.2 Discussion

Reports of *S. aureus* isolation are very widespread, with the organism found in association with various different samples. This organism is however both a leading cause of infection and a human commensal with human anterior nares as the primary reservoir of these organisms [26]. It is often difficult though to tell whether a specific strain of *S. aureus* is a commensal or a pathogen. Biofilm formation has however been associated with the pathogenicity of *S. aureus*. Studies assessing biofilm-forming potential in *S. aureus* using the Congo red agar method have reported varying rates ranging from 1.9% to 94% [27-33].




Fig. 1. Assessment of biofilm-forming potential of *S. aureus* isolates




Fig. 2. Source based effect on biofilm-forming potential




Fig. 3. Variation in degree of biofilm-forming potential

Majority of these studies involved only clinical isolates though some studied isolates from lab coats of medical students and another looked at organisms from surfaces in a dental clinic. The 58% rate of *S. aureus* isolates exhibiting biofilm-forming potential in this present study is more closely related to reports by Torlak and colleagues (46.9%) who studied *S. aureus* from surfaces in a dental clinic [29], and Khan and colleagues (47.71%) who looked at clinical *S. aureus* isolates in general [27]. It is also similar to

studies carried out in Nigeria which reported a 52.7% and 64% rate of biofilm-forming potential in clinical *S. aureus* isolates [33,34].

All these studies looked at *S. aureus* isolated from a variety of clinical sources and this could have had an impact on the variation in biofilm-forming potential observed. Ocal and colleagues had previously reported a significant relationship between invasive isolates and biofilm-forming potential [35]. These assertions were

corroborated by a more recent study observing that biofilm formation correlates with infection type [36]. Worryingly however, there have also been reports of a high association of biofilm-forming potential (61%) with *S. aureus* isolated from nasal cavities of healthy volunteers [37].

Studies exploring biofilm-forming potential in organisms from non-clinical sources were surprisingly lacking indicating an unexplored area of research.

4. CONCLUSION

This study reports a high association of biofilm-forming potential with *S. aureus* isolated from clinical rather than non-clinical settings, perhaps pointing at a role for biofilms in pathogenicity. These findings corroborate reports from other parts of the world. Further studies would however be needed to see if these findings are unique or representative of the Nigerian story.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Kobayashi SD, Malachowa N, DeLeo FR. Pathogenesis of *Staphylococcus aureus* abscesses. The American J Pathology. 2015;185(6):1518–1527.
2. Edwards AM, Massey RC, Clarke SR. Molecular mechanisms of *Staphylococcus aureus* nasopharyngeal colonization. Molecular Oral Microbiol. 2012;27(1):1–10.
3. Kane TL, Carothers KE, Lee SW. Virulence factor targeting of the bacterial pathogen *Staphylococcus aureus* for vaccine and therapeutics. Curr Drug Targets. 2018;19(2):111–127.
4. Aung MS, Urushibara N, Kawaguchiya M, Ito M, Habadera S, Kobayashi N. Prevalence and genetic diversity of Staphylococcal enterotoxin (-Like) genes sey, selw, selx, selz, sel26 and sel27 in community-acquired Methicillin-Resistant *Staphylococcus aureus*. Toxins. 2020; 12(5):347.
5. Li X, Huang T, Xu K, Li C, Li Y. Molecular characteristics and virulence gene profiles of *Staphylococcus aureus* isolates in Hainan, China. BMC Infect Dis. 2019; 19(1):873.
6. Xie X, Bao Y, Ouyang N, Dai X, Pan K, Chen B, et al. Molecular epidemiology and characteristic of virulence gene of community-acquired and hospital-acquired methicillin-resistant *Staphylococcus aureus* isolates in Sun Yat-sen Memorial hospital, Guangzhou, Southern China. BMC Infect Dis. 2016;16(1):339.
7. Hoveida L, Ataei B, Amirmozafari N, Noormohammadi Z. Species variety, antibiotic susceptibility patterns and prevalence of enterotoxin genes in staphylococci isolated from foodstuff in central Iran. Iran J. Public Health. 2020; 49(1):96–103.
8. Chao G, Bao G, Cao Y, Yan W, Wang Y, Zhang X, et al. Prevalence and diversity of enterotoxin genes with genetic background of *Staphylococcus aureus* isolates from different origins in China. Int. J. Food Microbiol. 2015;211:142–147.
9. Fooladvand S, Sarmadian H, Habibi D, van Belkum A, Ghaznavi-Rad E. High prevalence of methicillin resistant and enterotoxin gene-positive *Staphylococcus aureus* among nasally colonized food handlers in central Iran. European J Clin Microbiol Infect Dis. 2019;38(1):87–92.
10. Fri J, Njom HA, Ateba CN, Ndip RN. Antibiotic resistance and virulence gene characteristics of Methicillin-Resistant *Staphylococcus aureus* (MRSA) isolated from healthy edible marine fish Int J Microbiol; 2020.
11. Wang W, Bi L, Li X, Li F, Wang Y, Li H, et al. Antimicrobial resistance, virulence factors, and molecular characterization of methicillin-resistant *Staphylococcus aureus* isolates cultured from ready-to-eat foods. Wei sheng yan jiu Journal of Hygiene Res. 2020;49(1):56–62.
12. Oliveira PS, Souza SG, Campos GB, da Silva DC, Sousa DS, Araújo SP, et al. Isolation, pathogenicity and disinfection of *Staphylococcus aureus* carried by insects in two public hospitals of Vitória da Conquista, Bahia, Brazil. The Brazilian J Infect Dis. 2014;18(2):129–136.
13. Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, et al. Differential expression and roles of *Staphylococcus aureus* virulence determinants during colonization and disease MBio. 2015;6(1).
14. Jain A, Agarwal A. Biofilm production, a marker of pathogenic potential of colonizing and commensal staphylococci. J Microbiol Methods. 2009;76(1):88–92.

15. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. *Clin Microbiol Rev.* 2002; 15(2):167–193.
16. Cha JO, Yoo JI, Yoo JS, Chung HS, Park SH, Kim HS, et al. Investigation of biofilm formation and its association with the molecular and clinical characteristics of methicillin-resistant *Staphylococcus aureus*. *Osong Public Health Res Perspectives.* 2013;4(5):225–232.
17. Sanchez CJ, Mende K, Beckius ML, Akers KS, Romano DR, Wenke JC, et al. Biofilm formation by clinical isolates and the implications in chronic infections. *BMC Infect Dis.* 2013;13(1):47.
18. Graf AC, Leonard A, Schäuble M, Rieckmann LM, Hoyer J, Maass S, et al. Virulence factors produced by *Staphylococcus aureus* biofilms have a moonlighting function contributing to biofilm integrity. *Mol. Cell. Proteomics.* 2019;18(6):1036–1053.
19. Parastan R, Kargar M, Solhjoo K, Kafilzadeh F. A synergistic association between adhesion-related genes and multidrug resistance patterns of *Staphylococcus aureus* isolates from different patients and healthy individuals. *J Glob Antimicrob Resist.* 2020;22:379–385.
20. Gonzalez T, Stevens ML, Alarcon R, He H, Krone J, Spagna D, et al. Biofilm propensity of *Staphylococcus aureus* skin isolates is associated with increased severity and barrier dysfunction in the mechanisms of the progression of atopic dermatitis to asthma in children (MPAAC) Cohort. *J. Allergy Clin Immunol.* 2019; 143(2):AB64.
21. Cowan ST, Steel KJ. Manual for the identification of medical bacteria, 4th edition. London: Cambridge University Press, UK; 1985.
22. Cheesbrough M. District laboratory practice in tropical countries Part II. Cambridge University Press, UK; 2006.
23. Ochi P, Otokunefor K, Abu G. Diversity of biofilm producing bacteria in a drinking water distribution system in a sub-urban community in South-South Nigeria. *World Journal of Biomedical Research.* 2020; 7(1):8–14.
24. Darwish SF, Asfour HA. Investigation of biofilm-forming ability in *Staphylococci* causing bovine mastitis using phenotypic and genotypic assays. *The Scientific World Journal.* 2013;378492:1–9.
25. Otokunefor K, Melex DE, Abu GO. Biofilm forming potential of *Escherichia coli* from various sources. *J Life Biosci Res.* 2020;1(2):26–29.
26. Sakr A, Brégeon F, Mège JL, Rolain JM, Blin O. *Staphylococcus aureus* nasal colonization: An update on mechanisms, epidemiology, risk factors, and subsequent infections. *Front Microbiol.* 2018;9:2419.
27. Khan F, Shukla I, Rizvi M, Mansoor T, Sharma SC. Detection of biofilm formation in *Staphylococcus aureus*. Does it have a role in treatment of MRSA infections. *Trends Med Res.* 2011;6(2):116–123.
28. Neetu PJ, Murugan S. Biofilm formation by methicillin resistant *Staphylococcus aureus* and their antibiotic susceptibility pattern: An in vitro study. *Curr. Res. Bacteriol.* 2014;7:1–11.
29. Torlak E, Korkut E, Uncu AT, Şener Y. Biofilm formation by *Staphylococcus aureus* isolates from a dental clinic in Konya, Turkey. *J Infect Public Health.* 2017;10(6):809–813.
30. Kivanç SA, Arik G, Akova-Budak B, Kivanç M. Biofilm forming capacity and antibiotic susceptibility of *Staphylococcus* spp. with the *icaA/icaD/bap* genotype isolated from ocular surface of patients with diabetes. *Malawi Med J.* 2018;30(4):243–249.
31. Manandhar S, Singh A, Varma A, Pandey S, Shrivastava N. Biofilm producing clinical *Staphylococcus aureus* isolates augmented prevalence of antibiotic resistant cases in tertiary care hospitals of Nepal. *Frontiers in Microbiology.* 2018;9: 2749.
32. Batista IR, Prates AC, de Souza Santos B, Araújo JC, de Oliveira Bonfim YC, Rodrigues MV, et al. Determination of antimicrobial susceptibility and biofilm production in *Staphylococcus aureus* isolated from white coats of health university students. *Annals Clin. Microbiol. Antimicro.* 2019;18(1):1–7.
33. Ibrahim MM, Shettima A, Ngoshe IY, Abbas MI, Bello HS, Umoru AM, Isyaka TM. Phenotypic determination of biofilm formation and acquired resistance profile of clinically-derived bacterial isolates. *European J. Biol. Biotech.* 2020;1(4).
34. Abdulrahim U, Kachallah M, Rabiu M, Usman NA, Adeshina GO, Olayinka BO. Molecular detection of biofilm-producing *Staphylococcus aureus* isolates from national orthopaedic hospital Dala, Kano

- State, Nigeria. Open J. Med Microbiol. 2019;9(3):116–126.
35. Öcal DN, Dolapçı İ, Karahan ZC, Tekeli A. Stafilokok izolatlarının biyofilm oluşturma özelliklerinin araştırılması [Investigation of biofilm formation properties of *Staphylococcus* isolates]. Mikrobiyol Bul. 2017;51(1):10–19. Turkey
36. Kwiecinski JM, Jacobsson G, Horswill AR, Josefsson E, Jin T. Biofilm formation by *Staphylococcus aureus* clinical isolates correlates with the infection type. Infect Dis (Lond). 2019;51(6):446–451.
37. Devapriya F, Sajith P, Ranganathan R, Shanmugam J. Prevalence of biofilm and beta-lactamase producing *Staphylococcus* in nasal and throat isolates from healthy volunteers: A medical alert. Nepal J Med Sci. 2014;3(2):79–83.

© 2021 Otokunefor et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:

The peer review history for this paper can be accessed here:

<http://www.sdiarticle4.com/review-history/65069>